Literature DB >> 21396895

[The Spanish Society of Paediatric Infectious Diseases (SEIP) recommendations on the diagnosis and management of invasive candidiasis].

C Figueras1, C Díaz de Heredia, J J García, M Navarro, J Ruiz-Contreras, R Rossich, J Rumbao, M A Frick, E M Roselló.   

Abstract

Candida yeasts are ubiquitous commensals, which can cause opportunistic infection in any location of the body. The source of infection may be both endogenous and exogenous. Invasive candidiasis encompasses different entities ranging from invasive candidiasis to disseminated multiorgan infection. Invasive candidiasis is the third leading cause of nosocomial bloodstream infection and the fourth of all nosocomial infections. It is also the most common invasive fungal infection in non-neutropenic critically ill patients, with a remarkable increase in the last 20 years owing to the increased survival of these patients and to more complex diagnostic, therapeutic and surgical procedures. Its incidence in infants, according to recent reviews, stands at 38.8 cases/100,000 children younger than 1 year. Candida albicans remains the most frequent isolate in invasive infections, although infections caused by other species have risen in the last years, such as C. kruzsei, C. glabrata and C. parapsilosis; the latter causing invasive candidiasis mainly associated with central venous catheter management, especially in neonatal units. The overall mortality of invasive candidiasis is high, with 30-day mortality reaching 20-44% in some series involving paediatric patients. This report provides an update on incidence, epidemiology, clinical presentation, diagnosis, treatment and outcome of invasive infection by Candida spp. in the paediatric patient.
Copyright © 2010 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21396895     DOI: 10.1016/j.anpedi.2010.12.012

Source DB:  PubMed          Journal:  An Pediatr (Barc)        ISSN: 1695-4033            Impact factor:   1.500


  6 in total

1.  Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.

Authors:  Daniel Brustolin Ludwig; Luciana Erzinger Alves de Camargo; Najeh Maissar Khalil; Marcos Ereno Auler; Rubiana Mara Mainardes
Journal:  Mycopathologia       Date:  2018-03-01       Impact factor: 2.574

2.  T2Candida® to guide antifungal and lengh of treatment of candidemia in a pediatric multivisceral transplant recipient.

Authors:  Iker Falces-Romero; Emilio Cendejas-Bueno; María Laplaza-González; Luis Escosa-García; Cristina Schuffelmann-Gutiérrez; Belén Calderón-Llopis; Javier Pemán; Pedro de la Oliva; Julio García-Rodríguez
Journal:  Med Mycol Case Rep       Date:  2018-05-26

3.  Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis.

Authors:  Mahmoud Robati Anaraki; Masoud Nouri-Vaskeh; Shahram Abdoli Oskoei
Journal:  Clin Exp Pediatr       Date:  2020-05-14

4.  Risk factors for ophthalmologic involvement and ocular findings in patients diagnosed with fungemia in a high-complexity hospital in the city of Medellín, Colombia.

Authors:  Marcos Restrepo Arango; Juan Camilo Cadavid Usuga; Luis Fernando Velazquez Ossa; Jorge Hernando Donado Gómez; Laura Nataly Higuita Duque; Juan Pedro Neira Gomez
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 5.  Clinical practice update of antifungal prophylaxis in immunocompromised children.

Authors:  J T Ramos; C A Romero; S Belda; F J Candel; B Carazo Gallego; A Fernández-Polo; L Ferreras Antolín; C Garrido Colino; M L Navarro; O Nef; P Olbright; E Rincón-López; J Ruiz Contreras; P Soler-Palacín
Journal:  Rev Esp Quimioter       Date:  2019-09-11       Impact factor: 1.553

Review 6.  Fluconazole prophylaxis in preterm infants: a systematic review.

Authors:  Juliana Ferreira da Silva Rios; Paulo Augusto Moreira Camargos; Luísa Petri Corrêa; Roberta Maia de Castro Romanelli
Journal:  Braz J Infect Dis       Date:  2017-03-10       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.